Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
37
6
8
18
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
2.7%
1 terminated/withdrawn out of 37 trials
94.7%
+8.1% vs industry average
54%
20 trials in Phase 3/4
0%
0 of 18 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (37)
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
Role: collaborator
Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose
Role: lead
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Role: lead
Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study
Role: lead
Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease
Role: collaborator
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
Role: lead
Evaluation of a Remote Monitoring Application in the Follow-up of Patients With Active Inflammatory Bowel Diseases
Role: lead
Ibd CAncer and seRious Infections in France (I-CARE 2)
Role: lead
TRansmural hEaliNg Definition in CroHn's Disease (TRENCH 1)
Role: lead
VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER)
Role: lead
USTekinumab in Fistulising Perianal Crohn's Disease (USTAP)
Role: lead
Identification of Factors ASsociaTed With a Delayed Diagnosis in Crohn's Disease
Role: lead
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Role: lead
A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab
Role: lead
Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET
Role: lead
Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab
Role: lead
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis
Role: lead
Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)
Role: lead
IBD Cancer and Serious Infection in Europe
Role: lead
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
Role: lead